热门资讯> 正文

神经分泌报告Crenessity试验的积极结果

2025-07-14 21:37

Neurocrine Biosciences (NASDAQ:NBIX) reported one-year results from late-stage study of its experimental drug, Crenessity (crinecerfont), showing reductions in glucocorticoid dose and improvement in adults with congenital adrenal hyperplasia.
The study showed patients were able to maintain lower, more natural doses of glucocorticoids after treatment with Crenessity.
The company said that Crenessity has shown a good safety record and most common side effects were headaches and fatigue.

More on Neurocrine Biosciences

Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance
Neurocrine Biosciences Q1 2025 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。